Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $475,951 | 211 | 81.8% |
| Consulting Fee | $58,677 | 20 | 10.1% |
| Food and Beverage | $26,393 | 1,164 | 4.5% |
| Travel and Lodging | $19,256 | 173 | 3.3% |
| Honoraria | $800.00 | 1 | 0.1% |
| Education | $623.71 | 11 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $351,199 | 432 | $0 (2024) |
| Biogen, Inc. | $53,725 | 293 | $0 (2024) |
| Genentech USA, Inc. | $46,835 | 158 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $29,016 | 135 | $0 (2024) |
| EMD Serono, Inc. | $22,676 | 127 | $0 (2024) |
| Acorda Therapeutics, Inc | $18,963 | 47 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $17,480 | 59 | $0 (2019) |
| Teva Pharmaceuticals USA, Inc. | $15,139 | 63 | $0 (2019) |
| Celgene Corporation | $13,144 | 82 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $6,755 | 10 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,142 | 113 | EMD Serono, Inc. ($345.11) |
| 2023 | $2,626 | 120 | GENZYME CORPORATION ($481.15) |
| 2022 | $2,211 | 119 | Alexion Pharmaceuticals, Inc. ($421.25) |
| 2021 | $28,194 | 144 | GENZYME CORPORATION ($7,168) |
| 2020 | $27,825 | 93 | Celgene Corporation ($7,816) |
| 2019 | $109,926 | 251 | GENZYME CORPORATION ($58,996) |
| 2018 | $181,262 | 328 | GENZYME CORPORATION ($130,725) |
| 2017 | $227,514 | 412 | GENZYME CORPORATION ($151,322) |
All Payment Transactions
1,580 individual payment records from CMS Open Payments — Page 1 of 64
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $27.21 | General |
| 12/17/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $23.39 | General |
| Category: Immunology | ||||||
| 12/16/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $13.02 | General |
| Category: Neurology | ||||||
| 12/11/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $19.81 | General |
| Category: Immunology | ||||||
| 12/04/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $20.66 | General |
| 11/26/2024 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $22.68 | General |
| Category: Neurology | ||||||
| 11/22/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $13.48 | General |
| Category: Neuroscience | ||||||
| 11/22/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $2.36 | General |
| Category: Neuroscience | ||||||
| 11/22/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $2.14 | General |
| Category: Neuroscience | ||||||
| 11/19/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $22.16 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $13.35 | General |
| Category: Neurology | ||||||
| 11/15/2024 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $18.57 | General |
| Category: Neurology | ||||||
| 11/14/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $20.58 | General |
| 11/08/2024 | Genentech USA, Inc. | Enspryng (Biological) | Food and Beverage | In-kind items and services | $19.83 | General |
| Category: Immunology | ||||||
| 11/08/2024 | Genentech USA, Inc. | Enspryng (Biological) | Food and Beverage | In-kind items and services | $0.87 | General |
| Category: Immunology | ||||||
| 11/06/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $127.01 | General |
| 11/04/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $15.48 | General |
| Category: Neuroscience | ||||||
| 11/04/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $3.06 | General |
| Category: Neuroscience | ||||||
| 11/04/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $1.46 | General |
| Category: Neuroscience | ||||||
| 10/31/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $21.90 | General |
| Category: Rare Disease | ||||||
| 10/30/2024 | Sandoz Inc. | — | Food and Beverage | In-kind items and services | $16.03 | General |
| 10/29/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $21.48 | General |
| 10/28/2024 | Cycle Pharmaceuticals Inc | Tascenso ODT (Drug) | Food and Beverage | In-kind items and services | $21.43 | General |
| Category: NEUROLOGY | ||||||
| 10/25/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $17.25 | General |
| 10/24/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $23.39 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 132 | 14,051 | $2.3M | $615,740 |
| 2022 | 6 | 156 | 18,286 | $3.0M | $807,874 |
| 2021 | 6 | 202 | 26,241 | $4.3M | $1.1M |
| 2020 | 7 | 219 | 15,707 | $2.6M | $674,257 |
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2023 | 14 | 13,800 | $2.2M | $605,082 | 27.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 53 | 72 | $17,208 | $5,922 | 34.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 17 | 31 | $18,600 | $2,595 | 13.9% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 16 | 90 | $11,700 | $1,724 | 14.7% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 16 | 29 | $1,972 | $303.14 | 15.4% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 16 | 29 | $580.00 | $114.41 | 19.7% |
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2022 | 18 | 18,000 | $2.9M | $796,454 | 27.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 62 | 76 | $18,164 | $5,512 | 30.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 19 | 35 | $21,000 | $3,265 | 15.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 19 | 105 | $13,650 | $2,110 | 15.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 19 | 35 | $2,380 | $384.04 | 16.1% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2022 | 19 | 35 | $700.00 | $147.53 | 21.1% |
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2021 | 28 | 25,800 | $4.2M | $1.1M | 26.0% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 33 | 65 | $39,000 | $6,436 | 16.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 56 | 72 | $17,208 | $5,216 | 30.3% |
| 96415 | Infusion of chemotherapy into a vein | Office | 2021 | 28 | 168 | $21,840 | $3,625 | 16.6% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2021 | 28 | 56 | $3,808 | $664.56 | 17.5% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2021 | 29 | 80 | $1,600 | $233.49 | 14.6% |
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2020 | 23 | 15,300 | $2.5M | $656,633 | 26.4% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 36 | 99 | $59,400 | $9,778 | 16.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 62 | 80 | $19,120 | $4,390 | 23.0% |
| 96415 | Infusion of chemotherapy into a vein | Office | 2020 | 26 | 105 | $13,650 | $2,210 | 16.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 20 | 21 | $3,423 | $654.02 | 19.1% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2020 | 26 | 35 | $2,380 | $407.77 | 17.1% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2020 | 26 | 67 | $1,340 | $183.91 | 13.7% |
About Dr. Christopher Sheppard, MD
Dr. Christopher Sheppard, MD is a Internal Medicine healthcare provider based in Uniontown, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1306924964.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Sheppard, MD has received a total of $581,700 in payments from pharmaceutical and medical device companies, with $2,142 received in 2024. These payments were reported across 1,580 transactions from 36 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($475,951).
As a Medicare-enrolled provider, Sheppard has provided services to 709 Medicare beneficiaries, totaling 74,285 services with total Medicare billing of $3.2M. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Neurology
- Location Uniontown, OH
- Active Since 11/01/2006
- Last Updated 02/10/2015
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1306924964
Products in Payments
- LEMTRADA (Drug) $217,339
- AUBAGIO (Drug) $124,056
- OCREVUS (Biological) $37,862
- TECFIDERA (Drug) $31,263
- ACTHAR (Biological) $19,923
- ZEPOSIA (Drug) $18,987
- AMPYRA (Drug) $18,963
- Mavenclad (Biological) $16,787
- COPAXONE (Drug) $14,787
- TYSABRI (Biological) $14,627
- GILENYA (Drug) $10,809
- Non-Covered Product (Drug) $8,292
- MAYZENT (Drug) $7,378
- Mavenclad (Drug) $4,609
- DISEASE STATE (Drug) $3,579
- VUMERITY (Drug) $2,141
- Bafiertam (Drug) $800.00
- KESIMPTA (Drug) $749.97
- Ocrevus (Biological) $551.26
- SOLIRIS (Biological) $476.23
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Uniontown
Timothy Carrabine, Md, MD
Internal Medicine — Payments: $336,826
Dr. Mary Riley, D.o, D.O
Internal Medicine — Payments: $27,900
Richard Pish, Md, MD
Internal Medicine — Payments: $27,211
Michael Mulock, M.d, M.D
Internal Medicine — Payments: $20,001
Dr. Veerunna Yadagani, Md, MD
Internal Medicine — Payments: $11,658
Sridhar Patnam, M.d, M.D
Internal Medicine — Payments: $8,751